HK1218758A1 - 作為 激酶抑制劑的化合物 - Google Patents
作為 激酶抑制劑的化合物Info
- Publication number
- HK1218758A1 HK1218758A1 HK16106837.6A HK16106837A HK1218758A1 HK 1218758 A1 HK1218758 A1 HK 1218758A1 HK 16106837 A HK16106837 A HK 16106837A HK 1218758 A1 HK1218758 A1 HK 1218758A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- met
- compounds
- kinase inhibitors
- met kinase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38199510P | 2010-09-12 | 2010-09-12 | |
| US13/227,866 US8664244B2 (en) | 2010-09-12 | 2011-09-08 | Compounds as c-Met kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1218758A1 true HK1218758A1 (zh) | 2017-03-10 |
Family
ID=45811185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16106837.6A HK1218758A1 (zh) | 2010-09-12 | 2016-06-14 | 作為 激酶抑制劑的化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8664244B2 (zh) |
| EP (1) | EP2621904B1 (zh) |
| JP (1) | JP5939254B2 (zh) |
| KR (2) | KR101934243B1 (zh) |
| CN (2) | CN103328447B (zh) |
| AU (1) | AU2011299082B2 (zh) |
| BR (1) | BR112013005523B1 (zh) |
| CA (1) | CA2810528C (zh) |
| HK (1) | HK1218758A1 (zh) |
| NZ (1) | NZ609283A (zh) |
| WO (1) | WO2012034055A2 (zh) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012018639A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| EP2598660B1 (en) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| WO2013188752A2 (en) * | 2012-06-14 | 2013-12-19 | The Schepens Eye Research Institute | Treatment and prevention of retinal injury and scarring |
| US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
| CN104936946A (zh) * | 2013-01-18 | 2015-09-23 | 爱德程制药有限公司 | 制备抗肿瘤剂6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其结晶 |
| EP3632208A1 (en) | 2013-06-13 | 2020-04-08 | Biomatrica, INC. | Cell stabilization |
| CN104135504B (zh) | 2014-02-11 | 2015-12-30 | 腾讯科技（深圳）有限公司 | 一种基于应用的服务提供方法、装置及系统 |
| EP3154338B1 (en) | 2014-06-10 | 2020-01-29 | Biomatrica, INC. | Stabilization of thrombocytes at ambient temperatures |
| JP6827048B2 (ja) | 2015-12-08 | 2021-02-10 | バイオマトリカ，インク． | 赤血球沈降速度の低下 |
| CN106008339B (zh) * | 2016-06-08 | 2018-09-07 | 上海准视生物科技有限公司 | 一种放射性c-met靶向亲和小分子化合物及其应用 |
| CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| SG11201903463PA (en) * | 2016-10-18 | 2019-05-30 | Beijing Konruns Pharmaceutical Co Ltd | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same |
| CN108503650B (zh) * | 2017-02-27 | 2021-02-12 | 北京赛特明强医药科技有限公司 | 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用 |
| US11673897B2 (en) | 2018-01-26 | 2023-06-13 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| IL300824A (en) | 2018-01-26 | 2023-04-01 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| MA51672A (fr) * | 2018-01-26 | 2020-12-02 | Exelixis Inc | Composés destinés au traitement des troubles kinases-dépendants |
| PL3750893T3 (pl) | 2018-02-11 | 2023-07-17 | Beijing Scitech-Mq Pharmaceuticals Limited | Związek dioksazoliny, sposób jego wytwarzania oraz jego zastosowania |
| CN115057815A (zh) * | 2018-03-02 | 2022-09-16 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途 |
| WO2020027723A1 (en) * | 2018-08-01 | 2020-02-06 | Agency For Science, Technology And Research | Bicyclic compounds as kinase modulators, methods and uses thereof |
| CN113710322A (zh) * | 2019-01-25 | 2021-11-26 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230150956A1 (en) * | 2020-02-10 | 2023-05-18 | Stemsynergy Therapeutics, Inc. | Myc inhibitors and uses thereof |
| CN115135326B (zh) * | 2020-03-16 | 2024-09-13 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 |
| US20230263795A1 (en) * | 2020-06-02 | 2023-08-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody |
| CN117460509A (zh) * | 2021-06-23 | 2024-01-26 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物治疗I型神经纤维瘤病的用途 |
| WO2024114740A1 (zh) * | 2022-12-01 | 2024-06-06 | 正大天晴药业集团股份有限公司 | 喹诺林化合物治疗甲状腺癌的用途 |
| WO2024120483A1 (zh) * | 2022-12-08 | 2024-06-13 | 正大天晴药业集团股份有限公司 | 喹诺林化合物治疗卵巢癌的用途 |
| WO2024120520A1 (zh) * | 2022-12-09 | 2024-06-13 | 正大天晴药业集团股份有限公司 | 喹诺林化合物治疗小细胞肺癌的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH1596068A4 (zh) | 1968-10-25 | 1971-06-15 | ||
| AU5006793A (en) | 1992-08-14 | 1994-03-15 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University, The | Cdna clone encoding an expressible gaba transporter |
| EP2612853A1 (en) | 2003-09-26 | 2013-07-10 | Exelixis Inc. | c-Met modulators and methods of use |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| AU2006231646A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-Met modulators and methods of use |
| BRPI0610322B8 (pt) | 2005-05-20 | 2021-05-25 | Methylgene Inc | inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica |
| CA2608726C (en) | 2005-05-20 | 2013-07-09 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US8163923B2 (en) * | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8148532B2 (en) * | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| MX2011004018A (es) * | 2008-10-14 | 2011-06-24 | Ning Xi | Compuestos y metodos de uso. |
| KR20110133048A (ko) * | 2009-03-21 | 2011-12-09 | 닝 시 | 아미노 에스테르 유도체, 그의 염 및 이용 방법 |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
-
2011
- 2011-09-08 US US13/227,866 patent/US8664244B2/en active Active
- 2011-09-09 CN CN201180043667.4A patent/CN103328447B/zh active Active
- 2011-09-09 CN CN201510427250.8A patent/CN105153028B/zh active Active
- 2011-09-09 JP JP2013528342A patent/JP5939254B2/ja active Active
- 2011-09-09 NZ NZ609283A patent/NZ609283A/en not_active IP Right Cessation
- 2011-09-09 KR KR1020187004694A patent/KR101934243B1/ko active IP Right Grant
- 2011-09-09 AU AU2011299082A patent/AU2011299082B2/en not_active Ceased
- 2011-09-09 BR BR112013005523-5A patent/BR112013005523B1/pt active IP Right Grant
- 2011-09-09 KR KR1020137009160A patent/KR20140021509A/ko active Search and Examination
- 2011-09-09 CA CA2810528A patent/CA2810528C/en active Active
- 2011-09-09 EP EP11824198.3A patent/EP2621904B1/en active Active
- 2011-09-09 WO PCT/US2011/051061 patent/WO2012034055A2/en active Application Filing
-
2016
- 2016-06-14 HK HK16106837.6A patent/HK1218758A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103328447A (zh) | 2013-09-25 |
| US20120123126A1 (en) | 2012-05-17 |
| AU2011299082B2 (en) | 2016-09-29 |
| CN105153028A (zh) | 2015-12-16 |
| EP2621904A2 (en) | 2013-08-07 |
| WO2012034055A2 (en) | 2012-03-15 |
| CN103328447B (zh) | 2015-09-16 |
| JP5939254B2 (ja) | 2016-06-22 |
| BR112013005523A2 (pt) | 2016-05-03 |
| CA2810528C (en) | 2020-01-14 |
| WO2012034055A3 (en) | 2012-07-19 |
| KR101934243B1 (ko) | 2018-12-31 |
| KR20180021901A (ko) | 2018-03-05 |
| US8664244B2 (en) | 2014-03-04 |
| EP2621904A4 (en) | 2014-03-26 |
| JP2013537197A (ja) | 2013-09-30 |
| BR112013005523B1 (pt) | 2021-06-08 |
| CN105153028B (zh) | 2019-03-26 |
| CA2810528A1 (en) | 2012-03-15 |
| EP2621904B1 (en) | 2020-04-22 |
| AU2011299082A1 (en) | 2013-05-02 |
| NZ609283A (en) | 2015-02-27 |
| KR20140021509A (ko) | 2014-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1218758A1 (zh) | 作為 激酶抑制劑的化合物 | |
| IL265007B (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| IL257104A (en) | Macrocyclic compounds as trk kinase inhibitors | |
| HK1208442A1 (zh) | 作為 激酶抑制劑的取代的吡咯並嘧啶基氨基－苯並噻唑酮 | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| HK1192247A1 (zh) | 作為激酶抑制劑的雜環化合物 | |
| EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| AP3391A (en) | 2-Amino-4-arylthiazole compounds as TROA1 antagonists | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| EP2685992A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
| GB201009730D0 (en) | Kinase inhibitor compounds | |
| RS56275B1 (sr) | Makrociklička jedinjenja kao inhibitori trk kinaze |